COVID-19 Vaccinations With a Sweepstakes
NCT04951310 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 3827656
Last updated 2025-02-03
Summary
To reach herd immunity for COVID-19, experts estimate that 70% of the population will need to be vaccinated. However, vaccination rates have begun to slow down in the United States. The investigators will partner with Philadelphia to launch a COVID-19 vaccination sweepstakes, in which residents will be eligible to win if they have received at least one dose of the COVID-19 vaccine prior to a given drawing. Drawings will be held every two weeks; multiple prizes of various sizes will be awarded in each drawing. Half of the prizes in each size category in each drawing will be awarded to residents of a zip code that is randomly selected from a pre-defined list of under-vaccinated zip codes (this zip code will be announced at the start of each 2-week drawing period), the other half will be awarded to residents outside of that selected zip code. The investigators will analyze vaccination rates in Philadelphia as compared with neighboring regions before, during, and after the specified time period, as well as analyze vaccination rates in the three selected zip codes compared to the other zip codes that could have been targeted (the residual set of under-vaccinated zip codes) to determine the effectiveness of the sweepstakes at encouraging vaccinations.
Conditions
- Covid19
Interventions
- BEHAVIORAL
-
Philly Vax Sweepstakes
The "Philly Vax Sweepstakes" is a citywide sweepstakes designed to motivate Philadelphians to get vaccinated against COVID-19. A total of 36 vaccinated Philadelphians will win among three cash prize packages, distributed from the total cash pool. These 36 will be chosen over three drawings, with 12 residents chosen in each drawing.
Sponsors & Collaborators
-
Philadelphia Department of Public Health
collaborator OTHER_GOV - lead OTHER
Study Design
- Allocation
- RANDOMIZED
- Purpose
- HEALTH_SERVICES_RESEARCH
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2021-06-07
- Primary Completion
- 2021-08-14
- Completion
- 2021-08-14
Countries
- United States
Study Locations
More Related Trials
-
Immune Response In Children Revaccinated With Pneumococcal Conjugate Vaccine
NCT00853749 ·Status: COMPLETED ·Phase: PHASE3
-
MISP 60528 Pneumococcal Vaccination
NCT04845945 ·Status: TERMINATED
-
Safety, Tolerability, and Immunogenicity of V110 or V114 Co-administered With a Booster Dose of mRNA-1273 in Healthy Adults (V110-911)
NCT05158140 ·Status: COMPLETED ·Phase: PHASE3
-
Puerto Rico COVID-19 Vaccine Uptake Study
NCT05468021 ·Status: UNKNOWN ·Phase: NA
-
Evaluation of PCV21 Vaccination Among PPSV23-experienced, Immunocompromised Elderly Veterans
NCT06271681 ·Status: NOT_YET_RECRUITING ·Phase: PHASE4
-
COVID-19 Reactogenicity
NCT07051031 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE4
-
Variables Influencing Anti-COVID-19 Vaccinations Around the World: an Analysis Conducted on Aggregated Data Sourced From Institutional Databases to Understand Whether and How Different Variables Could Affect the Vaccine Coverage (WORLDCOV: Worldwide Determinants of COVID-19 Vaccination)
NCT05471635 ·Status: UNKNOWN
-
Safety Study of a Single Dose of Pneumococcal Whole-Cell Vaccine in Healthy Adults
NCT07059182 ·Status: COMPLETED ·Phase: PHASE1
-
Understanding Pneumococcal Carriage and Disease 2017-2020
NCT03102840 ·Status: UNKNOWN
-
Study Evaluating 13 Valent Pneumococcal Conjugate Vaccine With Trivalent Inactivated Influenza Vaccine
NCT00521586 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Learn About the Safety and Immune Response of a New Pneumococcal Vaccine in Adults
NCT06182124 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Revaccination With PNEUMOVAX(TM) 23 in Older Adults (V110-007)
NCT00560950 ·Status: COMPLETED ·Phase: PHASE3
-
Testing the Persuasiveness of Pro-inoculation Arguments
NCT05804825 ·Status: COMPLETED ·Phase: NA
-
Pre-approval Access for Janssen's COVID Vaccine VAC31518 for Treating Physician Use
NCT04817657 ·Status: NO_LONGER_AVAILABLE
-
Study Evaluating Persistence Of Antibody Response Elicited By 13vPnC In Healthy Adults Previously Vaccinated
NCT01025336 ·Status: COMPLETED ·Phase: PHASE3
-
Comparing Two Pneumococcal Vaccines in Adults With Chronic Obstructive Pulmonary Disease
NCT00457977 ·Status: COMPLETED ·Phase: PHASE3
-
Indirect Effects of Pneumococcal Vaccine on Nasopharyngeal Carriage
NCT01311024 ·Status: COMPLETED
-
A Phase 1, Randomized, Controlled, Observer-blinded Trial to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Conjugate Vaccine in Healthy Adults Aged 18 to 49 Years
NCT02955160 ·Status: COMPLETED ·Phase: PHASE1
-
Study Comparing a 13-valent Pneumococcal Conjugate Vaccine With 23-valent Pneumococcal Polysaccharide Vaccine in Adults
NCT00427895 ·Status: COMPLETED ·Phase: PHASE3
-
Effect of Obesity on Immune Response to Pneumovax 23
NCT02471014 ·Status: COMPLETED
-
Concomitant Administration of 13-valent Pneumococcal Conjugate Vaccine (13vPnC) With Influenza Vaccine in 23-valent Pneumococcal Polysaccharide (23vPS) Pre-vaccinated Adults.
NCT02124161 ·Status: COMPLETED ·Phase: PHASE4
-
Impact and Cost of a Pharmacist Pneumococcal Vaccination Program With PNEUMOVAX® 23 at an Urban Senior Center
NCT01944462 ·Status: COMPLETED ·Phase: PHASE4
-
The Effect of AUDIT and Feedback on Pneumococcal Vaccination Coverage
NCT05920499 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Study Evaluating the Safety, Tolerability and Immunogenicity of 13vPnC as a 2-Dose Regimen or With 23vPS
NCT00574548 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Learn About How 20-Valent Pneumococcal Conjugate Vaccine Works in a Real-world Setting
NCT05452941 ·Status: RECRUITING